CML Buster Foundation

30/06/2025

We are still in need of CML patients to participatevin this seminal study. Just need 30 min f yourvtime! For those that have already done so thank you.

📢 Help Shape the Future of CML Care! Your Voice Matters!
We are conducting a multi-country study to understand what matters most to people living with chronic phase CML when choosing treatments.
🔍 How does it work?
📊 Patients will complete a Discrete Choice Experiment (DCE), choosing between different hypothetical treatments with varying side effects.
⏳ Takes 20-30 minutes but could impact CML treatments for years to come!
🔗 Take part in this confidential online survey NOW: https://survey.valorem.health/cmlan-ohe-screener

27/01/2025

33 hours of travel, 16 hours of board meetings, great food and conversation with my awesome CML Advocates Network Family. Winging it home today...

We can't solve all the global CML patient issues but we can continue to improve their Quality of Life. Thank you CMLAN Steering Committee for all you do, so proud to be a small cog in this great organization. # cmlbusterstrong

12/06/2024

While this is for AML. The approach to research may be a novel and interesting one for CML TFR resistant patients.

21/01/2024

Great!!!!

21/10/2023

For those of you keeping up with the latest in CML trials and research papers. You should subscribe. Tim does a great job of covering the best of the best each month.

We’re pleased to share the CML ‘papers of the month’ as selected by Professor Timothy Hughes. Professor Hughes’ selection of relevant CML papers published in September include:

- Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib
Kok CH et al. Blood Cancer J, Sept 2023 (epub ahead of print) – open access publication
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495334/
- Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention
Shanmunagathan N et al. Haematologica, Sept 2023 – open access publication
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483360/
- Priapism at diagnosis of pediatric chronic myeloid leukemia: Data derived from a large cohort of children and teenagers and a narrative review on priapism management
Suttorp M et al. J Clin Med, July 2023 – open access publication
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380995/
- Population pharmacokinetics and pharmacogenetics analyses of dasatinib in Chinese patients with chronic myeloid leukemia
He S et al. Pharm Res, Sept 2023 (epub ahead of print)
https://link.springer.com/article/10.1007/s11095-023-03603-z

View the full list of papers via our website https://bit.ly/3bkWIWJ

18/09/2023

The most powerful, simple and trusted way to gather experience data. Start your journey to experience management and try a free account today.

06/08/2023

Leukemia is a serious rare blood cancer and often is detected during a CBC blood test. Externally most appear as normal and healthy even during treatment.

““Arriving at A&E all I could say was, “I’ve been told I have leukaemia and you’re expecting me.” I explained everything to the triage nurse, who said something like, “I think it’s very unlikely you’ve got leukaemia, you’re too young to have leukaemia.”””

06/08/2023

“CML Horizons Virtual Conference 2021 has now started with the CML 101 session, highlighting the basics of run by from USA. https://t.co/aLkqzs8glv”